lobbying_activities: 2817410
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2817410 | 4116df36-40b4-4c29-9917-e6798ecf7d6f | Q2 | AMERICAN PHARMACISTS ASSOCIATION | 3071 | AMERICAN PHARMACISTS ASSOCIATION | 2022 | second_quarter | CSP | S. 1388 -- Prescription Pricing for the People Act of 2021, a bill to require the Federal Trade Commission (FTC) to report about anticompetitive practices and other trends within the pharmaceutical supply chain that may impact the cost of prescriptions drugs. The FTC also must provide recommendations to increase transparency in the supply chain and prevent anticompetitive practices. S. 298/H.R. 1829 -- Pharmacy Benefit Manager Accountability Study Act of 2021, a bill to require the Government Accountability Office to report on the role of pharmacy benefit managers in the pharmaceutical supply chain and recommend legislative actions to lower the cost of prescription drugs. The report must address the use of rebates and fees, the average prior authorization approval time, and the use of step therapy within the 10 largest pharmacy benefit managers. S. 3399 To amend the Federal Food, Drug, and Cosmetic Act to provide a process to lock and suspend domain names used to facilitate the online sale of drugs illegally, and for other purposes. H.R. 7559 -- Required prescribing information for drugs subject to section 503(b)(1) may be made available solely by electronic means provided that the labeling complies with all applicable requirements of law, that the manufacturer affords prescribers and dispensers the opportunity to elect to also continue to receive all such information in paper form, or to request paper labeling on an as-needed basis, and after such request, and that the manufacturer promptly provides the requested information without additional cost. S. 4293 -- To prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs, and for other purposes. | HOUSE OF REPRESENTATIVES,SENATE | 35000 | 0 | 0 | 2022-07-12T15:45:48-04:00 |